Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ACTUATE THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for ACTUATE THERAPEUTICS, INC.

ACTU

ACTUATE THERAPEUTICS, INC.

About ACTUATE THERAPEUTICS, INC.

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing GSK-3 inhibitors, primarily elraglusib, for high-impact cancers like pancreatic ductal adenocarcinoma and pediatric malignancies. Its therapies aim to enhance immune response, inhibit tumor growth, and improve survival in difficult-to-treat cancers through innovative formulations and combination strategies, leveraging partnerships and regulatory incentives to accelerate development and approval.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ACTUATE THERAPEUTICS, INC.

1
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports $5.6 Million Net Loss in Q1 2026, Focuses on Clinical Development

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports $22.2 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports $5.95 Million Net Loss in Q2 2025, Seeks Additional Capital

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports $27.3 Million Net Loss for 2024, IPO Raises $22 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports Improved Financials, Net Loss, and Cash Reserves in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ACTUATE THERAPEUTICS, INC. Actuate Therapeutics Reports Significant Financial Challenges, Net Loss Increases Amid Clinical Trial Expenses and Cash Reserve Concerns

Via official filing (AI summary) | over 1 year ago | 0 comments